HC Wainwright Analysts Lift Earnings Estimates for INO

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Inovio Pharmaceuticals in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.20) for the quarter, up from their previous estimate of ($0.24). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.73) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.21) EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15.

A number of other equities research analysts have also weighed in on INO. Piper Sandler reissued an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Zacks Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 12th. Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and boosted their price objective for the company from $1.80 to $3.00 in a research report on Thursday. Finally, Weiss Ratings lowered Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $3.17.

Inovio Pharmaceuticals Trading Up 5.5%

Shares of NASDAQ:INO opened at $1.15 on Monday. The stock’s 50-day moving average price is $1.03 and its 200-day moving average price is $1.30. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98. The stock has a market capitalization of $118.91 million, a P/E ratio of -1.26 and a beta of 1.52.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Eversept Partners LP bought a new stake in Inovio Pharmaceuticals in the first quarter valued at $1,802,000. Virtu Financial LLC purchased a new position in Inovio Pharmaceuticals during the 4th quarter valued at $77,000. Jacobs Levy Equity Management Inc. bought a new position in Inovio Pharmaceuticals in the 3rd quarter worth $41,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Inovio Pharmaceuticals by 9.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 744,074 shares of the biopharmaceutical company’s stock worth $30,529,000 after purchasing an additional 61,297 shares during the period. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.